Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avadel Pharmaceuticals (AVDL) Cash from Investing Activities (2016 - 2022)

Historic Cash from Investing Activities for Avadel Pharmaceuticals (AVDL) over the last 13 years, with Q4 2022 value amounting to $22.9 million.

  • Avadel Pharmaceuticals' Cash from Investing Activities rose 4931.46% to $22.9 million in Q4 2022 from the same period last year, while for Dec 2022 it was $79.7 million, marking a year-over-year increase of 3999.54%. This contributed to the annual value of $51.8 million for FY2024, which is 20336.77% up from last year.
  • Latest data reveals that Avadel Pharmaceuticals reported Cash from Investing Activities of $22.9 million as of Q4 2022, which was up 4931.46% from $2.5 million recorded in Q3 2022.
  • In the past 5 years, Avadel Pharmaceuticals' Cash from Investing Activities ranged from a high of $42.3 million in Q1 2022 and a low of -$80.9 million during Q2 2020
  • In the last 5 years, Avadel Pharmaceuticals' Cash from Investing Activities had a median value of $11.6 million in 2021 and averaged $3.4 million.
  • In the last 5 years, Avadel Pharmaceuticals' Cash from Investing Activities soared by 315216.57% in 2018 and then tumbled by 100418.06% in 2020.
  • Over the past 5 years, Avadel Pharmaceuticals' Cash from Investing Activities (Quarter) stood at $16.2 million in 2018, then plummeted by 68.1% to $5.2 million in 2019, then skyrocketed by 40.06% to $7.2 million in 2020, then surged by 111.57% to $15.3 million in 2021, then surged by 49.31% to $22.9 million in 2022.
  • Its Cash from Investing Activities stands at $22.9 million for Q4 2022, versus $2.5 million for Q3 2022 and $12.0 million for Q2 2022.